IP Library Granted Patent US 9,682,132
Granted Patent B2
US 9,682,132 · App. 14/116,817 · Granted Jun 20, 2017

Compositions and methods relating to argininosucccinate synthetase

Inventors: Stanislav I. Svetlov (Alachua, FL); Victor Prima (Alachua, FL); Alvin Wang (Alachua, FL); Gabriel Molina (Alachua, FL); Kevin Ka-wang Wang (Gainesville, FL)
Assignee: BANYAN BIOMARKERS, INC
A61K38/53A61K38/45A61K47/48215C12Q1/25C12Y603/04005G01N33/573G01N2333/9015G01N2800/26G01N2800/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,682,132
App. No.
14/116,817
Granted
Jun 20, 2017
Kind
B2
Abstract

Processes and compositions for the therapeutic treatment of pathogenic Gram-negative bacterial infection are provided whereby arginino succinate synthetase or PEGylated arginino succinate synthetase is administered to a subject to inactivate endotoxin thereby reducing the likelihood of bacterial sepsis and improving patient outcome.

Claims (16)

1. A process of treating exposure of a subject to a bacterial endotoxin, comprising:

administering a therapeutically effective amount of argininosuccinate synthetase to a subject exposed to a bacterial endotoxin.

2. The process of claim 1 wherein said argininosuccinate synthetase is recombinantly expressed.

3. The process of claim 1 wherein said argininosuccinate synthetase is PEGylated.

4. The process of claim 1 wherein said argininosuccinate synthetase is PEGylated with a PEG comprising PEG 12 .

5. The process of claim 1 wherein said argininosuccinate synthetase is PEGylated with an unbranched PEG, a branched PEG, or combinations thereof.

6. The process of claim 5 wherein said argininosuccinate synthetase and said PEG are present in a ratio ranging from 1:1 to 1:400.

7. The process of claim 1 wherein said subject is infected with a pathogenic Gram-negative bacteria.

8. An isolated protein preparation for performing the process of claim 1 comprising:

a PEGylated argininosuccinate synthetase protein.

9. The preparation of claim 8 wherein said argininosuccinate synthetase is randomly PEGylated.

10. The preparation of claim 8 wherein said argininosuccinate synthetase is site-directed PEGylated.

11. The preparation of claim 10 wherein said argininosuccinate synthetase is site-directed PEGylated at one or more cysteines, lysines, histidines, or combinations thereof.

12. The preparation of claim 8 wherein said PEGylation comprises PEG 12 covalently associated with said argininosuccinate synthetase by an amide bond.

13. The preparation of claim 12 wherein said PEG 12 is a component of a branched PEG.

14. The preparation of claim 8 wherein said PEGylation comprises branched PEG.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2019
From: BANYAN BIOMARKERS, INC.
To: BIOREGENCY INC.
Reel/Frame 049495/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2018
From: BANYAN BIOMARKERS, INC.
To: BIOREGENCY INC.
Reel/Frame 047013/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2015
From: SVETLOV, STANISLAV I; PRIMA, VICTOR; WANG, ALVIN; MOLINA, GABRIEL; WANG, KEVIN KA-WANG
To: BANYAN BIOMARKERS, INC.
Reel/Frame 037171/0163 →
Continuity (2)
Provisional Application 61298309 · Jan 26, 2010
Related Publication 20140178351A1 · Jun 26, 2014